Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is a 4-methanolquinoline related to quinine. Indicated in the prevention and treatment of malaria. Oral administration, weekly dose (prevention) or single dose (treatment).
It is excreted in human milk in a clinically non-significant amount. (Edstein 1988)
It is an authorized medication in infants from 4 weeks of age or 5 kg of weight (BNF 2018). Since mefloquine can be safely prescribed to young infants, exposure to the small amount excreted in the mother’s milk is also safe. (CDC 2019)
Various medical societies and expert consensus consider the use of this medication safe during breastfeeding (WHO 2010), especially if infants are not premature or newborn and weigh more than 5 kg. (CDC 2019, Saito 2018, Chen 2010, WHO 2010, Adjei 2009)